Eupraxia Pharmaceuticals (EPRX) Liabilities and Shareholders Equity (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has reported Liabilities and Shareholders Equity for 5 consecutive years, with $145.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 397.22% year-over-year to $145.4 million; the TTM figure through Mar 2026 stood at $347.4 million (up 249.14% YoY), while the FY2025 annual figure was $86.2 million, up 146.55% from the prior year.
• Liabilities and Shareholders Equity rose to $145.4 million in Q1 2026 per EPRX's latest filing, from $86.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $145.4 million in Q1 2026 and bottomed at $10.4 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $47.5 million across 5 years, with a median of $29.2 million in 2025.
• On a YoY basis, Liabilities and Shareholders Equity climbed as much as 790.98% in 2025 and fell as far as 20.21% in 2025.
• Eupraxia Pharmaceuticals' Liabilities and Shareholders Equity stood at $19.1 million in 2022, then rose by 5.98% to $20.3 million in 2023, then jumped by 72.42% to $34.9 million in 2024, then surged by 146.55% to $86.2 million in 2025, then surged by 68.72% to $145.4 million in 2026.
• Business Quant data shows EPRX's Liabilities and Shareholders Equity at $145.4 million in Q1 2026, $86.2 million in Q4 2025, and $92.3 million in Q3 2025.